Compulsory Licensing in Brazil (2026): What Commercial Teams Need to Know After the Mounjaro Case

Compulsory licensing Brazil has moved from a theoretical risk to an active commercial threat in 2026. The Câmara dos Deputados fast-tracked urgency proceedings on a bill targeting Mounjaro (tirzepatide) patents in February 2026, reviving a legislative tool that Brazil has only formally exercised once before, the 2007 efavirenz compulsory licence. For in-house counsel, commercial directors and pharma licensing managers, the question is no longer whether compulsory licensing could disrupt existing agreements, but how quickly it could happen and what contractual protections need to be in place before it does.

This article delivers the practical playbook: a legal primer on the statutory framework, a timeline of current legislative activity, model contract clauses and a step-by-step action plan for commercial teams managing supply, pricing and IP exposure in Brazil.

TL;DR, Commercial Risk Summary

If your business holds, depends on, or distributes products under a patent licence in Brazil, treat the current legislative momentum as a trigger for immediate contract and supply-chain review. Here are five actions to prioritise now:

• Contract triage (within 24 hours). Identify every agreement, patent licences, supply contracts, distribution deals, that references a Brazilian patent potentially subject to compulsory licensing. Flag clauses on exclusivity, pricing, force majeure and termination.
• Supply mapping (within 72 hours). Chart upstream and downstream dependencies: who manufactures, who supplies active ingredients, and which distribution channels rely on exclusivity. Quantify inventory and assess alternative sourcing timelines.
• Notice processes (within 72 hours). Check contractual notice obligations. Prepare template notifications to counterparties confirming awareness of the legislative developments and reserving rights under existing clauses.
• Pricing modelling (within 14 days). Run financial scenarios for government-administered royalty rates, price caps under the Sistema Único de Saúde (SUS) procurement framework, and margin compression on downstream agreements.
• Escalation playbook (within 14 days). Establish a cross-functional response team (Legal, Supply, Finance, Regulatory, Commercial) with defined triggers, decision authority and a pre-approved communications plan for stakeholders.

What Is a Compulsory Licence in Brazil? Quick Legal Primer

A compulsory licence in Brazil is a government-authorised permission for a third party, or the state itself, to use a patented invention without the patent holder’s consent, subject to compensation. The statutory basis sits in Articles 68 to 74 of Law No. 9.279/1996, Brazil’s Industrial Property Law (Lei da Propriedade Industrial, or LPI). These provisions allow compulsory licensing on several distinct grounds, each carrying different triggers and commercial consequences.

It is important to distinguish between two mechanisms. A compulsory licence to a private third party (Art. 68) typically follows a finding of non-use or abuse of rights and is granted after an administrative process at the INPI. A government-use licence (Art. 71), sometimes called a public non-commercial use licence, allows the federal government to exploit a patent directly or through a designated third party in cases of national emergency or public interest, bypassing the standard petition process. The Mounjaro debate centres on the latter: broadening the government-use pathway for public health purposes.

How the INPI Process Works (High Level)

When a compulsory licence is sought through the standard administrative route, the INPI manages the process. In simplified terms, the steps are: (1) a qualified petitioner files a request with the INPI demonstrating that statutory grounds are met; (2) the patent holder is notified and given an opportunity to respond; (3) the INPI evaluates technical and commercial evidence, including market data; (4) if granted, the INPI sets the scope, duration and remuneration (royalty) for the licence; (5) the patent holder may appeal through administrative and judicial channels. For government-use licences under Art. 71, the process is faster, a presidential or ministerial decree can authorise exploitation directly, with remuneration determined subsequently.

Administrative timelines vary considerably, but the government-use pathway can be activated within weeks rather than months.

The Mounjaro Case and 2026 Legislative Activity, What Changed

The Mounjaro case in Brazil has become the focal point for a broader debate about compulsory licensing in the pharmaceutical sector. In early 2026, multiple bills were introduced in the Câmara dos Deputados targeting patents held by Eli Lilly for tirzepatide, marketed as Mounjaro, a GLP-1 receptor agonist used for type 2 diabetes and obesity. The political impetus reflected public pressure over drug pricing and access within the SUS framework.

Industry observers expect the legislative trajectory to accelerate further if public health advocacy groups maintain political pressure during the Senate phase. The proposed amendments go beyond a single product: early indications suggest they could broaden the statutory grounds for government-use licences to encompass additional therapeutic categories, including oncology and metabolic diseases. The likely practical effect will be to lower the threshold for future compulsory licensing actions across multiple drug classes.

Brazil’s only prior compulsory licence, for the antiretroviral efavirenz in 2007, demonstrated that the government will follow through when political conditions align. That precedent reshaped pricing dynamics across the entire HIV/AIDS supply chain and took years to fully unwind commercially. The Mounjaro case in Brazil signals a similar willingness to deploy the tool, this time in a therapeutic area with far larger patient populations and commercial value.

How a Compulsory Licence Would Affect Existing Patent and Supply Agreements

The commercial fallout from a compulsory licence in Brazil does not stop at the patent holder. It cascades through every agreement in the value chain, from upstream manufacturing licences to downstream distribution deals. Understanding these contractual pressure points is essential for any commercial team with pharma licensing Brazil exposure.

Patent licences (exclusive and non-exclusive). An exclusive patent licence becomes fundamentally compromised once the government authorises a third party to manufacture or import the same product. The licensee’s core commercial bargain, exclusivity in exchange for royalty payments, collapses. Contractual provisions on royalty recalculation, termination for frustration of purpose and assignment or consent clauses all come into play. Non-exclusive licences face margin pressure but are structurally less vulnerable.

Supply agreements and distribution contracts. Distributors with exclusive territory rights face competition from government-authorised generic suppliers, often at significantly lower price points. Existing agreements may contain force majeure clauses, but many do not specifically contemplate compulsory licensing as a qualifying event, creating immediate disputes about performance obligations, pricing adjustments and termination rights. Supply-continuity obligations may become impossible to fulfil if the patent holder reduces or redirects manufacturing capacity.

Third-party manufacturing and indemnities. Contract manufacturers engaged under licence may face conflicting obligations: the patent holder’s contractual requirements versus a government directive to supply product under the compulsory licence. Indemnity provisions, particularly IP indemnities, need careful review to determine whether they cover losses arising from government-mandated licensing actions.

Practical Examples, Upstream and Downstream Impacts

Scenario A: Multinational licensor with a local manufacturing partner. A global pharma company has licensed a Brazilian manufacturer to produce a patented drug exclusively for the domestic market. If a compulsory licence is issued, the government may designate additional manufacturers. The original licensee’s exclusivity evaporates, and the licensor’s royalty stream may be replaced by an administratively set rate, potentially far below the negotiated commercial royalty. Both parties face renegotiation pressure, and the licensor may seek to terminate.

Scenario B: Distributor with exclusive territory. A Brazilian distributor holds an exclusive import and distribution agreement for a patented medicine. Following a government-use licence, SUS procurement channels may source generic versions directly from government-designated suppliers. The distributor’s volumes collapse in the public-sector segment, triggering disputes over minimum-purchase commitments, price-review mechanisms and whether the compulsory licence constitutes force majeure under the contract.

Immediate Actions for Commercial Teams

When legislative or regulatory signals suggest that compulsory licensing Brazil may be activated, speed matters more than perfection. The following checklist breaks down actions into two phases: an initial 24–72 hour triage and a 2–4 week structured response.

Phase 1: 24–72 hour triage

• Legal review. Pull every contract in your Brazil portfolio that references a patent, exclusivity right or IP-dependent pricing mechanism. Highlight force majeure, material adverse change, termination and pricing clauses.
• Supply chain mapping. Identify every link in the upstream supply chain (API suppliers, contract manufacturers, logistics providers) and downstream chain (distributors, hospital networks, SUS procurement channels). Flag single points of failure.
• Inventory and demand snapshot. Quantify current stock levels, in-transit orders and forecast demand for the next 90 days. Determine whether stockpiling or accelerated ordering is commercially justified.
• Stakeholder notification. Issue preliminary internal alerts to Legal, Supply Chain, Finance, Regulatory Affairs and Commercial leadership. Prepare template external notices to counterparties reserving contractual rights.

Phase 2: 2–4 week structured response

• Financial modelling. Model the impact of government-administered royalty rates, SUS reference pricing and the entry of generic competitors on margin, revenue and contractual commitments.
• Regulatory liaison. Establish or strengthen channels with the INPI, Ministry of Health and ANVISA (sanitary surveillance) to monitor developments in real time.
• Insurance and indemnity review. Check whether political risk insurance, trade disruption coverage or contractual indemnities would respond to losses caused by a compulsory licence.
• Communications plan. Draft holding statements for investors, partners and media. Pre-approve escalation language for use if a bill passes or an INPI proceeding is initiated.

Clause Bank, What to Add or Change in Commercial Contracts Brazil

Commercial contracts Brazil that involve patented products or IP-dependent pricing need specific provisions to manage compulsory licensing risk. The following model clauses are designed to be adapted to your specific agreements. Each clause includes a negotiation note explaining the commercial rationale and common points of contention.

• Clause 1, Force Majeure (Compulsory Licensing Carve-Out). “For the purposes of this Agreement, ‘Force Majeure’ shall include the issuance of a compulsory licence, government-use licence or analogous governmental order under the Industrial Property Law of Brazil (Law No. 9.279/1996) affecting any patent underlying the Products.” Negotiation note: Patent holders typically resist including compulsory licensing as force majeure because it relieves performance obligations. Licensees and distributors should insist on explicit inclusion. Consider whether the clause suspends obligations or triggers termination rights.
• Clause 2, Emergency Price Review. “In the event that a compulsory licence or government-use licence is issued affecting the Products, either party may request an immediate price review. The parties shall negotiate in good faith to agree revised pricing within [30] days, failing which [arbitration / expert determination] shall apply.” Negotiation note: Specify the benchmark for revised pricing, government-administered royalty rate, SUS reference price, or cost-plus model. Include a fallback mechanism (arbitration or expert determination) to avoid deadlock.
• Clause 3, Suspension or Termination for Government Orders. “Either party may suspend performance of its obligations under this Agreement, without liability, for the duration of any government order requiring manufacture, sale or distribution of the Products under a compulsory licence. If such suspension continues for more than [90] days, either party may terminate upon [30] days’ written notice.” Negotiation note: The suspension period and termination threshold are heavily negotiated. Suppliers favour longer suspension periods; distributors want shorter windows and clear exit rights to pursue alternative supply.
• Clause 4, IP Indemnity and Cooperation (Know-How Disclosure Limits). “The Licensor’s obligation to indemnify the Licensee for IP-related losses shall extend to losses arising from the issuance of a compulsory licence, except to the extent such losses result from the Licensee’s own acts or omissions. Nothing in this Agreement shall require the Licensor to disclose manufacturing know-how, trade secrets or proprietary raw-material specifications beyond those expressly scheduled herein, including in response to a compulsory licence order.” Negotiation note: Leading commentary from Brazilian IP practitioners confirms that patent owners are under no automatic obligation to provide manufacturing know-how or raw materials under a compulsory licence. However, government orders may seek to compel cooperation. This clause establishes the contractual boundary while preserving indemnity coverage.
• Clause 5, Compulsory-Licence Notification Obligation. “Each party shall notify the other in writing within [5] business days of becoming aware of any petition, governmental proceeding or legislative action that could result in a compulsory licence affecting the Products. Failure to provide timely notice shall constitute a material breach.” Negotiation note: Early warning is critical. Tie notification failure to material breach to ensure enforceability. Consider adding an obligation to share copies of any government correspondence.
• Clause 6, Governing Law and Dispute Resolution Contingency. “This Agreement is governed by the laws of [Brazil / chosen jurisdiction]. Any dispute arising from or in connection with the issuance of a compulsory licence shall be resolved by [ICC arbitration seated in São Paulo / Brazilian courts of the [district]].” Negotiation note: Arbitration offers confidentiality and neutrality but adds cost. Brazilian courts have jurisdiction over compulsory licence validity challenges in any event. Consider a two-track approach: arbitration for commercial disputes between the parties; local courts for challenges to the government order itself.

Negotiation Playbook and Dispute Preparedness

If compulsory licensing Brazil moves from legislative proposal to executive action, commercial teams need a structured negotiation and dispute-readiness plan. The following framework applies whether you are the patent holder, a licensee or a distributor.

Step 1: Preserve evidence immediately. Document manufacturing capability, production capacity, cost structures and supply-chain arrangements. If the government challenges whether local manufacturing can meet demand, this evidence supports arguments on remuneration levels and transition timelines.

Step 2: Engage counterparties proactively. Do not wait for formal notices. Open dialogue with licensing partners, suppliers and distributors to assess their positions. Key questions to raise include:

• Does the counterparty consider the compulsory licence a force majeure event under the existing contract?
• What pricing adjustments, if any, does the counterparty intend to seek?
• Is the counterparty willing to enter a standstill agreement while the legislative process unfolds?
• Does the counterparty intend to participate in INPI proceedings or challenge the government order?

Step 3: Evaluate litigation triggers. Identify the point at which negotiation is exhausted and formal dispute resolution becomes necessary. For patent holders, this may include challenging the legality of the decree or the adequacy of compensation. For licensees and distributors, triggers may include breach of exclusivity, failure to adjust pricing or refusal to cooperate on supply transition. Arbitration under ICC or CIESP/FIESP rules is common for commercial contracts in Brazil; judicial proceedings are required for direct challenges to government acts.

Step 4: Build an escalation matrix. Define clear thresholds, financial, operational and reputational, at which each level of response is activated (internal review → board notification → external counsel engagement → formal proceedings). Assign decision authority to named individuals and set response timelines measured in days, not weeks.

What to Watch Next, Legislative Signals and Practical Monitoring

Commercial teams should establish a structured monitoring cadence to track the trajectory of compulsory licensing Brazil legislation. The key sources and signals to watch include:

• Câmara dos Deputados and Senado Federal legislative trackers. Monitor bill status, committee assignments, voting schedules and amendment texts. The Senado’s legislative portal provides docket updates that can be tracked electronically.
• Presidential action. Watch for presidential messages, decree proposals and statements from the Ministry of Health signalling intent to invoke Art. 71 government-use powers independently of the legislative process.
• INPI proceedings. Monitor the INPI’s Revista da Propriedade Industrial for any compulsory licence petitions or ex officio actions related to tirzepatide or related patents.
• Press and industry commentary. Agência Brasil provides reliable coverage of congressional proceedings. Specialist outlets (Chambers, Licks Attorneys, Tavares IP) offer timely analysis of proposed amendments and their commercial implications.

Industry observers expect the next critical milestone to be the Senate committee vote on the consolidated bill. A recommended monitoring cadence is daily during active voting periods and weekly otherwise, with automated alerts set for key bill numbers and patent references.

Conclusion

Compulsory licensing Brazil is no longer an abstract policy debate, it is an operational risk that demands immediate attention from commercial, legal and supply-chain teams. The three priority actions are clear: audit every IP-linked contract in your Brazil portfolio for compulsory-licensing exposure; update force majeure, pricing and termination clauses using the model language above; and establish a cross-functional monitoring and escalation framework before the next legislative milestone arrives. Companies that prepare now will be in a materially stronger position to protect margins, preserve relationships and navigate whatever the Brazilian Congress and executive decide in the months ahead.

For jurisdiction-specific guidance, the commercial practice area and Brazil lawyer directory on Global Law Experts connect teams with qualified local counsel experienced in patent licensing Brazil, regulatory risk and commercial dispute resolution.

Sources

1. Law No. 9.279/1996 (Industrial Property Law), Planalto
2. INPI, Types of Agreements (English)
3. WIPO Lex, Brazil Industrial Property Law
4. Agência Brasil, Câmara Aprova Urgência para Votar Quebra de Patente do Mounjaro
5. Chambers, Compulsory Licensing in Brazil 2026: The Mounjaro Case
6. Kasznar Leonardos, Patent Owners Under No Obligation to Provide Know-How
7. Tavares IP, Brazil’s Congress Fast-Tracks Bill on Compulsory Licensing
8. Licks Attorneys, Compulsory Licensing in Brazil 2026